The US government has purchased 650,000 additional doses of Eli Lilly’s neutralising antibody bamlanivimab (LY-CoV555) 700 mg for treating COVID-19 for $812.5 million.
The doses will be delivered through January 31, 2021, with at least 350,000 of the additional doses delivered in December 2020.
Bamlanivimab recently received emergency use authorization for the treatment of mild to moderate COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalisation.
“Given the significant increase in COVID-19 cases and hospitalizations in the U.S., we are doing everything possible to quickly provide more bamlanivimab doses to Americans,” said David A. Ricks, Lilly’s Chairman and CEO.
“We are proud of our work to deploy significant manufacturing capacity and remain committed to enabling widespread and equitable access to bamlanivimab.
“The US government’s effort to allocate bamlanivimab around the country is critical to ensuring it reaches patients who need it the most.”
This purchase brings the total doses purchased by the US government to 950,000.